ValiRx Plc (AIM: VAL) has highlighted its indirect 5.55% shareholding in Ambrose Healthcare following the private pharmaceutical company’s agreement to acquire AM-Pharma for up to €161 million, drawing investor attention
ValiRx Secures Second European Patent for Cytolytix Cancer-Killing Peptide
ValiRx PLC (AIM: VAL) has received notice that the European Patent Office intends to grant a second patent covering the cancer-killing peptide being developed by its majority-owned subsidiary Cytolytix.
ValiRx plc (AIM: VAL) New Evaluation and Material Transfer Agreement
ValiRx plc (AIM: VAL), a life sciences company focusing on early-stage cancer therapeutics and women’s health and The Royal Institute for the Advancement of Learning/McGill University (“McGill”), a Canadian based
genedrive plc (AIM: GDR) MT-RNR1 ID Kit in Dublin’s Rotunda Hospital
Genedrive® MT-RNR1 ID Kit implemented at Dublin’s Rotunda Hospital
Genedrive Shares Jump 22% on Talks Over £1 Million Shareholder Loan
Genedrive PLC (AIM: GDR) shares soared 22% to 1.04p after the diagnostics company confirmed it is in talks with major shareholder David Nugent regarding a potential £1 million loan to
genedrive plc (AIM: GDR) Comment re: Share Price Movement
genedrive plc (AIM: GDR), the point of care pharmacogenetic testing company, notes the fall in the Company’s share price on 13 August 2025 which it believes was connected to postings
genedrive PLC (AIM: GDR) Expects Revenue to Double as Commercial Momentum Builds
Genedrive PLC (AIM: GDR), the developer of rapid genetic testing technology, expects total income for the year ended 30 June to rise to around £1 million, up from £0.5 million
ValiRx Plc (AIM: VAL): Ambrose Extends Option on VAL401
Ambrose Healthcare Exercise Option on VAL 401 Out License Agreement for £16 Million plus Royalties
Genedrive PLC (AIM:GDR) received European regulatory approval
Genedrive wins EU approval for rapid genetic test aimed at stroke and heart attack care
Genedrive PLC (AIM:GDR) CYP2C19-ID Kit adopted for routine clinical use
North West Anglia Foundation NHS Trusts’ Peterborough City Hospital implements the Genedrive® CYP2C19-ID Kit for routine clinical use
ValiRx PLC (AIM:VAL) Conclusion of Evaluation Project
London, UK – ValiRx Plc (AIM: VAL), a life science company focusing on early-stage cancer therapeutics and women’s health, provides the following update at the conclusion of the Evaluation project from
ValiRx PLC (AIM:VAL) Update on proposed sub-license of VAL201
London, UK – ValiRx Plc (AIM: VAL), a life science company focusing on early-stage cancer therapeutics and women’s health announces that, further to the amendment to the Letter of Intent (“LOI”)